CHIESI FARMACEUTICI S.P.A.
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1935-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.chiesigroup.com
Clinical Trials
473
Active:296
Completed:139
Trial Phases
5 Phases
Phase 1:245
Phase 2:50
Phase 3:55
+2 more phases
Drug Approvals
22
EMA:14
NMPA:8
Drug Approvals
Beclometasone Dipropionate and Formoterol Fumarate Powder for Inhalation
- Product Name
- 倍氯米松福莫特罗吸入粉雾剂
- Approval Number
- 国药准字HJ20240144
- Approval Date
- Dec 1, 2024
NMPA
Beclometasone Dipropionate Suspension for Inhalation
- Product Name
- 吸入用丙酸倍氯米松混悬液
- Approval Number
- 国药准字HJ20130214
- Approval Date
- Feb 14, 2023
NMPA
Beclometasone Dipropionate，Formoterol Fumarate and Glycopyrrolate Inhalation Aerosol
- Product Name
- 倍氯福格吸入气雾剂
- Approval Number
- 国药准字HJ20220035
- Approval Date
- Apr 12, 2022
NMPA
Budesonide Pressurised Inhalation Solution
- Product Name
- 布地奈德吸入气雾剂
- Approval Number
- H20120320
- Approval Date
- Feb 13, 2020
NMPA
Clinical Trials
Distribution across different clinical trial phases (361 trials with phase data)• Click on a phase to view related trials
Phase 1
245 (67.9%)Phase 3
55 (15.2%)Phase 2
50 (13.9%)Phase 4
10 (2.8%)Not Applicable
1 (0.3%)Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
Not yet recruiting
- Conditions
- Fabry DiseasePregnancyPregnancy Complications
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 10
- Registration Number
- NCT06941025
- Locations
- 🇬🇧
No physical study sites - Decentralized, web-based registry, London, United Kingdom
A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa
Phase 3
Recruiting
- Conditions
- Epidermolysis BullosaJunctional Epidermolysis BullosaEpidermolysis Bullosa, DystrophicEpidermolysis Bullosa, JunctionalSkin AbnormalitiesCongenital AbnormalitiesConnective Tissue DiseaseCollagen DiseasesSkin DiseasesGenetic Diseases, Inborn
- Interventions
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 6
- Registration Number
- NCT06917690
- Locations
- 🇯🇵
Kurume University Hospital, Fukuoka, Japan
🇯🇵Niigata University Medical and Dental Hospital, Niigata, Japan
🇯🇵Hokkaido University Hospital, Sapporo-shi, Japan
A Comparison Study Between Adolescents With Asthma and Adults With Asthma on How They Absorb, Metabolise and Eliminate CHF 6001
- First Posted Date
- 2025-03-28
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 50
- Registration Number
- NCT06900816
- Locations
- 🇧🇬
Medical Centre Comac Medical Ltd., Sofia, Krasno Selo District, Bulgaria
Effect of Cyclosporine Drug Interaction on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers. Drug-Drug Interaction 2 (DDI2) Study
Phase 1
Recruiting
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 24
- Registration Number
- NCT06892756
- Locations
- 🇧🇬
Medical Centre Comac Medical Ltd, Sofia, Bulgaria
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF10073 After Single and Multiple Doses in Healthy Volunteers
Phase 1
Recruiting
- Conditions
- Pulmonary Fibrosis
- Interventions
- Drug: CHF10073 (Part 1 - SAD)Drug: Placebo (Part 1 - SAD)Drug: CHF10073 (Part 2 - MAD)Drug: Placebo (Part 2 - MAD)Drug: CHF10073 (Part 3)
- First Posted Date
- 2024-12-24
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 132
- Registration Number
- NCT06746064
- Locations
- 🇧🇪
SGS Belgium NV Clinical Pharmacology Unit, Edegem, Belgium
- Prev
- 1
- 2
- 3
- 4
- 5
- 34
- Next
News
Elgan Pharma and Chiesi Begin Phase 3 Trial of ELGN-2112 for Intestinal Malabsorption in Preterm Infants
Elgan Pharma and Chiesi Group have dosed the first patients in FIT-PIV, a Phase 3 trial evaluating ELGN-2112 for intestinal malabsorption in preterm infants.